Cancer Biology: Angiogenesis, VEGF, and Anti-Angiogenic Therapies

Added:

Angiogenesis
Targeting Vessels

Angiogenesis

0:03
Playing Section
  • 1

    Tumors trigger VEGF pathways to grow new blood vessels.

  • 2

    Multiple proteins aid vessel invasion and survival.

Basic cellular biology of cancer, including uncontrolled cell division, tumor progression, and the concept of metastasis.
The anatomy and physiology of the circulatory system, specifically how blood vessels (endothelial cells and capillaries) deliver oxygen and nutrients to tissues.
Fundamental concepts of cell signaling, including how extracellular ligands bind to cell-surface receptors to trigger intracellular cascades.
The cellular response to hypoxia, particularly how low oxygen levels trigger transcription factors like Hypoxia-Inducible Factor (HIF).
Mechanisms of drug resistance to anti-angiogenic therapies, such as compensatory upregulation of alternative angiogenic factors like FGF and PDGF.
The clinical concept of 'vessel normalization' and how anti-angiogenic drugs are strategically combined with chemotherapy and immunotherapy.
The systemic side effects of VEGF inhibitors, including hypertension, arterial thromboembolism, and impaired wound healing.
Next-generation angiogenesis inhibitors, including endogenous inhibitors like angiostatin and endostatin, as well as novel gene-therapy delivery methods.
424.2K views3.8Klikes3:59@MechanismsInMedicineOriginal Release: 2012-10-29

Tumors require new blood vessel formation (angiogenesis) to sustain growth beyond a certain size; tumor cells secrete vascular endothelial growth factor (VEGF) and related proteins that stimulate endothelial cell proliferation, basement membrane degradation via matrix metalloproteinases, vessel permeability, and survival of new blood vessels, making VEGF signaling a key therapeutic target in cancer treatment.